You are here

semaglutide

Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study

Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study

Fierce Pharma

Flag link:

In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug

In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug

Endpoints

clinical trials

Flag link:

Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready

Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready

Fierce Pharma

Flag link:

5 Biggest New Drugs of 2018

5 Biggest New Drugs of 2018

Motley Fool

Gilead Sciences

Bictegravir/F/TAF

Flag link:

These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News

These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News

Investors Business Daily

Flag link:

Novo gains FDA OK for semaglutide

Novo gains FDA OK for semaglutide

BioPharma Dive

type 2 diabetes

Flag link:

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Endpoints

Flag link:

With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch

With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch

Fierce Biotech

Flag link:

Novo's experimental diabetes drug likely to compete with Trulicity

Novo's experimental diabetes drug likely to compete with Trulicity

Medical Marketing and Media

Flag link:

FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key

FDA gives Novo Nordisk top grades for its diabetes drug semaglutide, but retinopathy remains key

Endpoints

diabetic retinopathy

Flag link:

Diabetes drugs must prove their value to payers, analysts say

Diabetes drugs must prove their value to payers, analysts say

Medical Marketing and Media

Flag link:

Novo focuses on new obesity therapy Semaglutide

Novo focuses on new obesity therapy Semaglutide

GoInPharma

Flag link:

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

Endpoints

Flag link:

Puma's FDA Decider And Semaglutide's Head-To-Head Battle

Puma's FDA Decider And Semaglutide's Head-To-Head Battle

Seeking Alpha

Puma Biotechnology

Flag link:

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

Reuters

Flag link:

3 Tremendously Promising Diabetes Drugs Potentially on the Way

3 Tremendously Promising Diabetes Drugs Potentially on the Way

Motley Fool

Lexicon Pharmaceuticals

Flag link:

Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent

Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent

Yahoo/Reuters

Flag link:

Novo Nordisk notches another phase 3 success for GLP-1 drug

Novo Nordisk notches another phase 3 success for GLP-1 drug

BioPharma Dive

Flag link:

Novo Nordisk's weekly diabetes drug goes 5-for-5 in Phase III

Novo Nordisk's weekly diabetes drug goes 5-for-5 in Phase III

Fierce Biotech

Flag link:

Pages